RecruitingPhase 1NCT06228924
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
Studying Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tenaya Therapeutics
- Intervention
- TN-401(genetic)
- Enrollment
- 15 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2029
Study locations (7)
- University of California San Francisco, San Francisco, California, United States
- University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- NYU Langone Health, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06228924 on ClinicalTrials.govOther trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT03593317Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVDHospices Civils de Lyon
- RECRUITINGNANCT05209776Local Inflammation in Arrhythmogenic Right Ventricular CardiomyopathyUniversity Hospital, Toulouse
- RECRUITINGNCT03049254Mayo AVC Registry and BiobankMayo Clinic
See all trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant →